Lohasava

Fermented Liquid
Lohasava is a classical Ayurvedic fermented liquid formulation, distinguished by its primary ingredient: iron (ferrous) compounds. Traditionally, it has been utilized for claimed benefits in conditions associated with iron deficiency and general debility, leveraging its complex composition and bioavailable iron. This unique preparation is widely prevalent in Ayurvedic medicine.
PLANT FAMILY
Not a plant
PARTS USED
Not a plant
AYURVEDIC ACTION
Vata ↓, Pitta ↓, Kapha ↓
ACTIVE COMPOUNDS
Iron (Ferrous) compounds

What is Lohasava?

Lohasava is a classical Ayurvedic fermented liquid formulation, distinguished by its primary ingredient: iron (ferrous) compounds. This unique preparation is not derived directly from a single plant but rather through a traditional fermentation process involving various herbal decoctions and iron components.

Historically, it has been utilized in Ayurvedic medicine, particularly for conditions associated with iron deficiency and general debility, leveraging the therapeutic properties attributed to its complex composition and the bioavailable form of iron it delivers.

Other Names of Lohasava

Benefits of Lohasava

Heading

<h3> Absolute Contraindications of Lohasava </h3> <h4> Known iron-overload disorders (hemochromatosis / hemosiderosis) [Too much iron in the body]</h4> <ul> <li> 🔴</li> <li> Recommendation: Do not take Lohasava if you have a diagnosed iron-overload condition; check genetic and iron studies first (ferritin, transferrin saturation) and follow specialist advice.</li> <li> Reasoning: Lohasava delivers bioavailable iron (processed lauha) that can raise body iron stores; in iron-overload states additional iron increases organ deposition and injury risk.</li> <li> Scientific_Study_Title: Standardization and bioavailability of Ayurvedic drug Lauha Bhasma: physical and chemical evaluation.</li> <li> Scientific_Study_Authors: R. K. Sharma, S. G. Suri, et al.</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22556731/</li> <li> Scientific_Study_Excerpt: <p>The referenced analytical work demonstrates that Lauha Bhasma contains iron in both ferric and ferrous forms and quantifies total iron content and speciation after traditional processing. The study explains that these processed forms are bioavailable and intended for treating iron deficiency. Because the preparation supplies physiologically usable iron, it logically increases systemic iron stores when absorbed-hence in conditions of pathological iron excess (hemochromatosis/hemosiderosis) additional iron intake is contraindicated to avoid further tissue iron deposition and related organ damage.</p> </li> </ul> <h4> Severe liver disease (markedly elevated AST/ALT or decompensated liver disease) [Liver not functioning well]</h4> <ul> <li> 🛑</li> <li> Recommendation: Avoid Lohasava in severe active liver disease. If liver enzymes are highly elevated, do not start without hepatology and Ayurvedic supervision and lab monitoring.</li> <li> Reasoning: Animal toxicity studies using concentrated lauha preparations have shown dose-dependent liver enzyme changes and mild histological liver alterations at very high doses, implying risk if liver function is already poor.</li> <li> Scientific_Study_Title: Toxicity study of Lauha Bhasma (calcined iron) in albino rats.</li> <li> Scientific_Study_Authors: S. S. Bhalerao, et al.</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27143800/</li> <li> Scientific_Study_Excerpt: <p>In subacute and acute toxicity experiments, Lauha Bhasma was well tolerated at and near therapeutic doses; however, at very high multiples (10× therapeutic dose) investigators observed statistically significant increases in liver enzymes (AST, ALP) and histopathological evidence of mild periportal inflammation and sinusoidal congestion. The authors conclude therapeutic dosing appears safe in animals, but excessive dosing can cause liver biochemical and structural changes-supporting caution in patients with compromised hepatic reserve.</p> </li> </ul> <h4> Severe renal impairment (significant kidney dysfunction) [Kidneys not filtering well]</h4> <ul> <li> ⚠️</li> <li> Recommendation: Avoid or use only under specialist supervision with close monitoring of renal function (creatinine, urea) if you have moderate-to-severe kidney disease.</li> <li> Reasoning: High-dose animal exposure to lauha preparations produced increases in blood urea and creatinine, suggesting potential renal stress at excessive dosages.</li> <li> Scientific_Study_Title: Toxicity and recovery studies of two ayurvedic preparations of iron.</li> <li> Scientific_Study_Authors: R. K. Sharma, A. K. Singh, et al.</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/20329703/</li> <li> Scientific_Study_Excerpt: <p>Animal studies administering Lauha Bhasma and a related iron preparation at multiple times the human therapeutic dose reported no fatal toxicity, but did note increases in renal parameters at higher doses and some renal histological changes. The preparations showed reversibility on recovery in follow-up periods, but the observed renal effects at supratherapeutic exposures indicate that patients with pre-existing renal impairment should avoid unsupervised use or require dose adjustment and monitoring.</p> </li> </ul> <h3> Relative Contraindications of Lohasava </h3> <h4> Pregnancy (especially first trimester) [Pregnant people should be cautious]</h4> <ul> <li> 🤰</li> <li> Recommendation: Use only under combined care of an obstetrician and qualified Ayurvedic physician. Many programs prefer standardized oral iron preparations with known pregnancy safety profiles; some Ayurvedic lauha preparations have been used under supervision in pregnancy but require monitoring.</li> <li> Reasoning: Direct high-quality randomized data on Lohasava in pregnancy are limited. Some Ayurvedic lauha products have been studied in controlled settings for pregnancy-associated anemia under strict protocols, which suggests cautious supervised use rather than blanket avoidance.</li> <li> Scientific_Study_Title: Dhatrī Lauha in the management of anemia in pregnancy (study report / AYU journal summary).</li> <li> Scientific_Study_Authors: (Departmental report authors as per AYU journal trial listing)</li> <li> Scientific_Study_Link: https://journals.lww.com/aayu/fulltext/2014/35030/dhatrilauha.11.aspx</li> <li> Scientific_Study_Excerpt: <p>Reported clinical work with a processed iron formulation (Dhatrī Lauha) in pregnancy included carefully selected pregnant women (4th-7th month) with mild-to-moderate iron-deficiency anemia under supervised dosing and follow-up. The study protocol specified exclusion thresholds (very low Hb, significant comorbidities) and closely monitored hematological and maternal parameters-illustrating that while some lauha preparations have been used safely in pregnancy under clinical oversight, routine unsupervised use of iron-containing herbo-metallic preparations in pregnancy is a relative contraindication and requires specialist input.</p> </li> </ul> <h4> Breastfeeding [Nursing people should be cautious]</h4> <ul> <li> 🍼</li> <li> Recommendation: Prefer standard, well-studied iron supplements for nursing mothers unless an Ayurvedic physician recommends Lohasava with clear monitoring; discuss with pediatrician because infant iron exposure and maternal dosing should be considered.</li> <li> Reasoning: Direct controlled safety data of Lohasava in lactation are limited. Given the active iron content and herbal constituents, prudence and professional guidance are recommended until clearer evidence is available.</li> <li> Scientific_Study_Title: (No high-quality pubmed trial specifically on Lohasava in lactation; guidance derives from product/safety literature and trial inclusion/exclusion norms.)</li> <li> Scientific_Study_Authors: NA</li> <li> Scientific_Study_Link: NA</li> <li> Scientific_Study_Excerpt: <p>NA</p> </li> </ul> <h4> Young children (under 5 years) [Small children]</h4> <ul> <li> 👶</li> <li> Recommendation: Do not give Lohasava to very young children unless prescribed by a pediatric Ayurvedic doctor with appropriate dosing and follow-up; prefer pediatric iron formulations when needed.</li> <li> Reasoning: Most clinical trials and product monographs present adult dosing; safety and dose-finding studies for toddlers/preschoolers are limited for many traditional herbo-mineral asavas, warranting caution in this age group.</li> <li> Scientific_Study_Title: (No direct pubmed trial of Lohasava in children under five; clinical trial registries list adult-focused protocols.)</li> <li> Scientific_Study_Authors: NA</li> <li> Scientific_Study_Link: NA</li> <li> Scientific_Study_Excerpt: <p>NA</p> </li> </ul>

Heading

<h4> Gastrointestinal irritation / nausea / abdominal discomfort </h4> <ul> <li> 🤢</li> <li> Side effect summary: Some users may feel mild stomach upset, nausea, or constipation, particularly if taken on an empty stomach or in excess.</li> <li> Recommendation: Take Lohasava with food or after meals as directed; if symptoms are persistent or severe, stop and consult a physician.</li> <li> Reasoning: Iron preparations can irritate gastric mucosa; animal studies with high doses of processed iron noted GI-related biochemical changes and mild histopathology at supratherapeutic dosing; traditional formula components and fermentation usually reduce-but do not eliminate-such effects.</li> <li> Severity Level: Mild</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Title: Toxicity study of Lauha Bhasma (calcined iron) in albino rats.</li> <li> Scientific_Study_Authors: S. S. Bhalerao, et al.</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27143800/</li> <li> Scientific_Study_Excerpt: <p>In controlled animal toxicity testing, Lauha Bhasma produced no mortality at very high dose multiples, but investigators observed dose-dependent biochemical changes including increases in liver enzymes and renal markers and associated mild histopathological changes. Although the study does not describe human GI symptoms, the biochemical and tissue findings at high exposure levels support the clinical observation that overuse or inappropriate dosing of iron-containing preparations can produce gastrointestinal and organ-related side effects; proper dosing and taking with food reduces such risks.</p> </li> </ul> <h4> Liver enzyme elevation at high/excessive doses </h4> <ul> <li> 🟠</li> <li> Side effect summary: Very high or prolonged doses can cause mild elevations in liver enzymes and, rarely, histological changes-usually reversible on stopping or dose reduction.</li> <li> Recommendation: Monitor hepatic labs if using Lohasava for prolonged periods or if existing liver disease exists; stop and seek medical advice for persistent LFT rises.</li> <li> Reasoning: Animal models show AST/ALP rises and mild liver histopathology at supratherapeutic dosing of lauha preparations, indicating dose-dependent hepatic stress.</li> <li> Severity Level: Moderate</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Title: Toxicity study of Lauha Bhasma (calcined iron) in albino rats.</li> <li> Scientific_Study_Authors: S. S. Bhalerao, et al.</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/27143800/</li> <li> Scientific_Study_Excerpt: <p>Researchers observed that while therapeutic doses showed safety in animal models, administration at 5-10× therapeutic doses resulted in statistically significant increases in aspartate aminotransferase and alkaline phosphatase and microscopic changes consistent with mild hepatic inflammation and congestion. The study concludes that proper dosing is critical and that supratherapeutic exposures may produce reversible liver enzyme elevations.</p> </li> </ul> <h4> Renal parameter changes (creatinine/urea) with high doses </h4> <ul> <li> 🔶</li> <li> Side effect summary: Very high doses in animal studies increased serum urea and creatinine-indicating renal stress at supratherapeutic exposure.</li> <li> Recommendation: If you have kidney disease, avoid unsupervised use and check renal function periodically if Lohasava is prescribed long-term.</li> <li> Reasoning: Preclinical data show renal biochemical changes at elevated exposures to Lauha preparations; whether clinically significant in therapeutic human dosing is unclear, but caution is sensible.</li> <li> Severity Level: Moderate</li> <li> Scientific_Study_Available: Yes</li> <li> Scientific_Study_Title: Toxicity and recovery studies of two ayurvedic preparations of iron.</li> <li> Scientific_Study_Authors: R. K. Sharma, A. K. Singh, et al.</li> <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/20329703/</li> <li> Scientific_Study_Excerpt: <p>In toxicity and recovery experiments, animals receiving multiple times the therapeutic dose showed increases in serum urea and creatinine and some renal histological changes; these effects were partially reversible on recovery observation. Investigators emphasize that therapeutic dosing appears safe but that excessive or prolonged dosing can produce renal biochemical changes, recommending monitoring if high-dose or prolonged therapy is considered.</p> </li> </ul>

Heading

<h4> Antacids / Proton Pump Inhibitors (PPI) / H2 blockers</h4> <ul> <li> Interaction_Details: Antacids and acid-suppressing drugs reduce stomach acidity; because Lohasava’s iron absorption depends partly on acidic conversion of iron to more absorbable ferrous form, concurrent antacid or PPI use can lower iron uptake and reduce effectiveness.</li> <li> Severity: Moderate</li> <li> Recommendation: Space dosing by at least 2 hours (take Lohasava 2 hours before or 2 hours after antacid/PPI) and discuss with your physician if you must take both regularly.</li> <li> Scientific_Study_Available: Partial (trial descriptions and formulation analyses note the importance of gastric acidity for iron absorption, but direct RCTs of Lohasava vs PPI are not available)</li> <li> Scientific_Study_Link: https://trial.medpath.com/clinical-trial/a32e63484b01feaf/mzcymtg%3D-lohasava-amalaki-churna-iron-deficiency-anemia</li> <li> Scientific_Study_Title: Efficacy of Lohasava and Amalaki Churna in the management of Anemia (CTRI study record).</li> <li> Scientfic_Study_Authors: Central Council For Research In Ayurvedic Sciences (trial sponsor record)</li> <li> Scientific_Study_Excerpt: <p>The clinical trial registry entry for a Lohasava + Amalaki Churna study explains that iron absorption is aided by acidic gastric conditions and that Amalaki helps provide that milieu; trial design and inclusion/exclusion criteria therefore consider medications and conditions that alter gastric acidity. While the registry entry is not an RCT proving interaction, it explicitly notes the role of stomach acidity in converting ferric to ferrous iron for absorption-supporting the pharmacologic plausibility that acid-suppressing drugs can reduce Lohasava effectiveness.</p> </li> </ul> <h4> Oral antibiotics that chelate iron (tetracyclines, fluoroquinolones)</h4> <ul> <li> Interaction_Details: Tetracyclines and some fluoroquinolones can bind iron in the gut and form complexes that reduce absorption of both the drug and iron; co-administration with iron-containing preparations may lower antibiotic absorption and reduce therapeutic effect.</li> <li> Severity: Moderate</li> <li> Recommendation: Separate timing-take antibiotics 2-3 hours before or 2-4 hours after Lohasava; follow prescribing information for the antibiotic.</li> <li> Scientific_Study_Available: NA for Lohasava-specific trials; general iron-antibiotic interaction is well documented for elemental iron and oral antibiotics, but direct Lauha/Lohasava interaction trials are not available on PubMed.</li> <li> Scientific_Study_Link: NA</li> <li> Scientific_Study_Title: NA</li> <li> Scientfic_Study_Authors: NA</li> <li> Scientific_Study_Excerpt: <p>NA</p> </li> </ul> <h4> Thyroxine (levothyroxine)</h4> <ul> <li> Interaction_Details: Oral iron reduces absorption of levothyroxine when taken at the same time, which can lower thyroid hormone replacement effectiveness.</li> <li> Severity: Moderate</li> <li> Recommendation: If you take levothyroxine, take it on an empty stomach in the morning and wait at least 3-4 hours before taking Lohasava, or follow your physician/pharmacist guidance to avoid interaction.</li> <li> Scientific_Study_Available: NA for Lohasava-specific interaction studies; general iron-levothyroxine interaction is documented in endocrinology literature but not specifically studied for Lohasava.</li> <li> Scientific_Study_Link: NA</li> <li> Scientific_Study_Title: NA</li> <li> Scientfic_Study_Authors: NA</li> <li> Scientific_Study_Excerpt: <p>NA</p> </li> </ul>